FDA Approves Oveporexton for Narcolepsy Type 1; HHS Recommends DEA Scheduling
On August 5, 2026, the U.S. Food and Drug Administration announced approval of a new drug application for Orzeyful (oveporexton) to treat narcolepsy type 1 in adults. The Department of Health and Human Services…